Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis
ConditionCardiac Amyloidosis
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-95
SponsorCentral Hospital, Nancy, France
About this trial
Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.
Eligibility criteria
Qualifiers
Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.
Disqualifiers
Patients who object to the use of their data
Trial design
Treatments tested in this trial
- bone scintigraphy
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov